Cargando…

Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma

OBJECTIVES: To develop a surveillance protocol with improved cost-effectiveness after radical nephroureterectomy (RNU), as the cost-effectiveness of oncological surveillance after RNU remains unclear. RESULTS: Of 426 patients, 109 (26%) and 113 (27%) experienced visceral and intravesical recurrences...

Descripción completa

Detalles Bibliográficos
Autores principales: Momota, Masaki, Hatakeyama, Shingo, Yamamoto, Hayato, Iwamura, Hiromichi, Tobisawa, Yuki, Yoneyama, Tohru, Yoneyama, Takahiro, Hashimoto, Yasuhiro, Koie, Takuya, Iwabuchi, Ikuya, Ogasawara, Masaru, Kawaguchi, Toshiaki, Ohyama, Chikara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955429/
https://www.ncbi.nlm.nih.gov/pubmed/29796171
http://dx.doi.org/10.18632/oncotarget.25198
_version_ 1783323710616240128
author Momota, Masaki
Hatakeyama, Shingo
Yamamoto, Hayato
Iwamura, Hiromichi
Tobisawa, Yuki
Yoneyama, Tohru
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Koie, Takuya
Iwabuchi, Ikuya
Ogasawara, Masaru
Kawaguchi, Toshiaki
Ohyama, Chikara
author_facet Momota, Masaki
Hatakeyama, Shingo
Yamamoto, Hayato
Iwamura, Hiromichi
Tobisawa, Yuki
Yoneyama, Tohru
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Koie, Takuya
Iwabuchi, Ikuya
Ogasawara, Masaru
Kawaguchi, Toshiaki
Ohyama, Chikara
author_sort Momota, Masaki
collection PubMed
description OBJECTIVES: To develop a surveillance protocol with improved cost-effectiveness after radical nephroureterectomy (RNU), as the cost-effectiveness of oncological surveillance after RNU remains unclear. RESULTS: Of 426 patients, 109 (26%) and 113 (27%) experienced visceral and intravesical recurrences, respectively. The pathology-based protocol found significant differences in recurrence-free survival in the visceral recurrence but not in the intravesical recurrence. The medical costs per visceral recurrence detected were high, especially in normal-risk (≤ pT2N0, LVI-, SM-) patients. We developed a risk score associated with visceral recurrence using Cox regression analysis. The risk score-based protocol was significantly more cost-effective than the pathology-based protocol. Estimated cost differences reached $747,929 per recurrence detected, a suggested 55% reduction. MATERIALS AND METHODS: We retrospectively evaluated 426 patients with RNU for upper tract urothelial carcinoma (UTUC) without distant metastasis at 4 hospitals. Patients with routine oncological follow-up were stratified into normal-, high- and very high-risk groups according to a pathology-based protocol utilizing pathological stage, lymphovascular invasion (LVI) and surgical margin (SM). Cost-effectiveness of the pathology-based protocol was evaluated, and a risk score-based protocol was developed to optimize cost-effectiveness. Risk scores were calculated by summing up risk factors independently associated with recurrence-free survival. Patients were stratified by low-, intermediate- and high-risk score. Estimated cost per recurrence detected by pathology-based and risk score-based protocols was compared. CONCLUSIONS: A risk score-stratified surveillance protocol has the potential to reduce over investigation during follow-up, making surveillance more cost-effective.
format Online
Article
Text
id pubmed-5955429
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59554292018-05-24 Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma Momota, Masaki Hatakeyama, Shingo Yamamoto, Hayato Iwamura, Hiromichi Tobisawa, Yuki Yoneyama, Tohru Yoneyama, Takahiro Hashimoto, Yasuhiro Koie, Takuya Iwabuchi, Ikuya Ogasawara, Masaru Kawaguchi, Toshiaki Ohyama, Chikara Oncotarget Research Paper OBJECTIVES: To develop a surveillance protocol with improved cost-effectiveness after radical nephroureterectomy (RNU), as the cost-effectiveness of oncological surveillance after RNU remains unclear. RESULTS: Of 426 patients, 109 (26%) and 113 (27%) experienced visceral and intravesical recurrences, respectively. The pathology-based protocol found significant differences in recurrence-free survival in the visceral recurrence but not in the intravesical recurrence. The medical costs per visceral recurrence detected were high, especially in normal-risk (≤ pT2N0, LVI-, SM-) patients. We developed a risk score associated with visceral recurrence using Cox regression analysis. The risk score-based protocol was significantly more cost-effective than the pathology-based protocol. Estimated cost differences reached $747,929 per recurrence detected, a suggested 55% reduction. MATERIALS AND METHODS: We retrospectively evaluated 426 patients with RNU for upper tract urothelial carcinoma (UTUC) without distant metastasis at 4 hospitals. Patients with routine oncological follow-up were stratified into normal-, high- and very high-risk groups according to a pathology-based protocol utilizing pathological stage, lymphovascular invasion (LVI) and surgical margin (SM). Cost-effectiveness of the pathology-based protocol was evaluated, and a risk score-based protocol was developed to optimize cost-effectiveness. Risk scores were calculated by summing up risk factors independently associated with recurrence-free survival. Patients were stratified by low-, intermediate- and high-risk score. Estimated cost per recurrence detected by pathology-based and risk score-based protocols was compared. CONCLUSIONS: A risk score-stratified surveillance protocol has the potential to reduce over investigation during follow-up, making surveillance more cost-effective. Impact Journals LLC 2018-05-01 /pmc/articles/PMC5955429/ /pubmed/29796171 http://dx.doi.org/10.18632/oncotarget.25198 Text en Copyright: © 2018 Momota et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Momota, Masaki
Hatakeyama, Shingo
Yamamoto, Hayato
Iwamura, Hiromichi
Tobisawa, Yuki
Yoneyama, Tohru
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Koie, Takuya
Iwabuchi, Ikuya
Ogasawara, Masaru
Kawaguchi, Toshiaki
Ohyama, Chikara
Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma
title Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma
title_full Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma
title_fullStr Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma
title_full_unstemmed Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma
title_short Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma
title_sort risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955429/
https://www.ncbi.nlm.nih.gov/pubmed/29796171
http://dx.doi.org/10.18632/oncotarget.25198
work_keys_str_mv AT momotamasaki riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT hatakeyamashingo riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT yamamotohayato riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT iwamurahiromichi riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT tobisawayuki riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT yoneyamatohru riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT yoneyamatakahiro riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT hashimotoyasuhiro riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT koietakuya riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT iwabuchiikuya riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT ogasawaramasaru riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT kawaguchitoshiaki riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma
AT ohyamachikara riskstratifiedsurveillanceprotocolimprovescosteffectivenessafterradicalnephroureterectomyinpatientswithuppertracturothelialcarcinoma